Scientists at the Johns Hopkins Kimmel Cancer Center (MD, USA) have completed a proof-of-principle study with results indicating the potential for a urine test for prostate cancer. The study identified cancer-specific changes in urinary RNAs and metabolites.
Liquid biopsy to predict clinical response to immunotherapy in metastatic non-small cell lung cancer?
Results from research carried out at Perelman School of Medicine (University of Pennsylvania, PA, USA) and the Abramson Cancer Center (PA, USA) suggest that a blood test could be used to predict the clinical response to immunotherapy in non-small cell lung cancer.
In the future, a simple blood test could help to reduce heart disease deaths, say researchers from Newcastle University (UK) who have linked high levels of amyloid-β in the blood to cardiovascular disease.
A large multicentric study has identified a new biomarker that could be used in the differential diagnosis of vascular dementia.
Researchers are presenting the details of a new blood-based assay that utilizes cell-free DNA to identify the methylation signals of gastrointestinal cancers at the Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 23–25 January 2020.
Quantitative proteomics identifies biomarker for acute rickettsial spotted fever infections, say researchers
Researchers based at University of Texas Medical Branch (TX, USA) report the use of quantitative proteomics studies to identify a potential biomarker for rickettsial infections, including Mediterranean spotted fever and Rocky Mountain spotted fever.
In this instalment of Robert Macneill’s (Covance) column, Robert explores the potential information to be gleaned from calibration curves and how these insights could possibly fuel innovation in the field of biomarker quantification.
Researchers have designed a non-invasive and inexpensive chip-based optical biosensor with increased sensitivity to detect the presence and progression of cancerous tumors. The cancer protein biomarker S100A4 was detected at concentrations of 300 picomolar in a synthetic urine sample.
Researchers from the University of Texas Southwestern Medical Center (TX, USA) have identified a biomarker blood test that could identify individuals with early-stage heart disease in need of treatment.
Researchers have analyzed flotillin levels in samples from individuals with and without Alzheimer’s disease (AD) and determined that serum flotillin levels are negatively associated with brain amyloid deposition. Flotillin could serve as a biomarker to estimate brain amyloid deposition, potentially aiding the early diagnosis of AD.